KENNETH ROBERT BEER, M.D.
CURRICULUM VITAE

Kenneth Beer, MD, PA
1500 N. Dixie Hwy. Suite 305
West Palm Beach, FL, 33401
Office: (561) 655-9055 **Fax** : (561) 655-9233
Website beerdermatology.com **email**: kenbeer@aol.com

Education:

08/1985-05/1989	M.D., University of Pennsylvania School of Medicine
08/1981-05/1985	A.B., Duke Scholar, Elected Phi Beta Kappa, Duke University
	B.S., Zoology, Duke University

Certification:

10/1993	Board Certified in Dermatology by the American Board of Dermatology
10/1995	Board Certified in Dermatopathology, by the American Board of Dermatology
10/2001 / 10/2012	Re-Certified in Dermatology with specialization in Dermatologic Surgery and Dermatopathology

Academic Positions:

01/2012 - present	Clinical Associate, Department of Dermatology, University of Pennsylvania
01/1998 - present	Consulting Associate, Department of Medicine, Duke University
01/1995 - present	Voluntary Clinical Instructor, University of Miami

Postgraduate Training and Fellowships:

08/1989-05/1990	Graduate Hospital, Internal Medicine
08/1990-05/1993	Dermatology Residency, University of Chicago
08/1993-05/1994	Fellow in Dermatopathology, University of Chicago

Licensure:

Florida Board of Health	1991- present
California Board of Medicine	1991- present
Illinois Department of Professional Regulation	1991- present
New York State Department of Medicine	1991- present

3/15/24

Curriculum Vitae Kenneth Beer, M.D.

Memberships:

Fellow - American Academy of Dermatology

American Society for Dermatopathology

American Society for Mohs Surgery

American Society for Dermatologic Surgery

American Society for Laser Medicine & Surgery Inc.

International Association for the Study of Lung Cancer

Florida Society for Dermatology and Dermatologic Surgery

Association of Clinical Research Professionals

DIA organization

Editorial Board:

Advisory Board, New Beauty Magazine

Editorial Board, Cosmetic Dermatology Journal

Contributing Editor, The Journal of Dermatologic Surgery

Editorial Board, The Dermatologist

Editorial Panel, Journal of Drugs in Dermatology

Editorial Board, The Journal of Clinical and Aesthetic Dermatology

Corporate:

Scientific Advisory Board, Anterios Corporation 2009-2015
Scientific Advisory Board, Aclaris Corporation 2012-2018
Founder and Director, Cosmetic Bootcamp LLC, The Leading Training Seminar for Cosmetic Specialists 2004-Present
Founder and Owner, Scientific Skin, LLC. 2012-present
Research Institute of the Southeast, Medical Director 2014-present

Clinical Research:

FDA/IND Trials

Investigator (IIT) Kybella for the treatment of Flank Fat
Investigator (IIT) A single-Center, study of the safety and efficacy of Juvedérm Voluma for the treatment of hypognathism
Investigator-(IIT) A Single-Center, Latisse (Bimatoprost .03% ophthalmic solution) for the treatment of hypotrichosis of the eyebrows: Latisse vs. placebo.
Investigator-(IIT)A Single-Center, Open-label Clinical Study to Collect Preliminary Data on the Use of Sculptra Injections for the Treatment of Moderate to Severe Scarring from Acne or Varicella.

Investigator Initiated Trials:

Investigator-Protocol ZyclaraBCC2013 Imiquimod 3.75% Cream (Zyclara) open-lable for The Treatment of Superficial Basal Cell Carcinoma.
Investigator- A Split-Face Study Comparing the Adverse Events Associated with Radiesse when Injected into the Nasolabial Folds with a Cannula vs. Needle Delivery System
Investigator- A Single Center Site Open Label of Dysport to treat brow ptosis and have the outcome of brow lifting with use of Dysport.
Investigator- Single Center Quantitative Assessment of Actinic Keratosis after single treatment with Levulan and BLU-U photodynamic therapy following split face pretreatment using a plastic microneedle array on one side compared with standard treatment (no microneedle) on the other side.
Investigator- Single Center Site Dysport PerlaneL2010) Upper Face Remodeling with Perlane-L and Dysport.
Investigator- Effect of Skin Cooling on Patient Discomfort During Periocular Botulinum Toxin Type A Injection.
Investigator- A phase IV Multi Center Study Evaluating the Ability of Vivete Home Care Regime to extend the Benefits Associated with Botox and Juvederm Ultra in office Procedures When Used Concurrently
Sub-Investigator- A Single-Center Evaluation of the Fraxel Restore Laser System for Treatment of Burn Scars.
Investigator-A Multi-Center Neocutis Bio-restorative Eye Cream in the Treatment of Skin around Eye.
Investigator-Protocol for the Evaluation of Radiesse for the Treatment of Mid-Face Descent (Malar Augmentation).
Investigator-Protocol A Randomized, Evaluator-Blind, Comparison of the Safety and Efficacy of Restylane and Hylaform Plus for the Correction of Nasolabial Folds.
Investigator- A Clinical Study Evaluating the Safety and Efficacy of Botox Cosmetic compared with Placebo Injection, Strivectin-SD Topical Treatment, Wrinkle Relax Topical Treatment and Hydroderm Topical Treatment for the Temporary Improvement in the Appearance of Moderate to Severe Glabellar Rhytids.

Sponsored Trials:

Principal Investigator with Research Institute of the Southeast (Phase 2b) Protocol CBL-0205: A Phase 2b, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection Compared with CBL-A1 and CBL-A2 for Reducing Abdominal Subcutaneous Fat.

Principal Investigator with Research Institute of the Southeast- Protocol 43N3US2204 (Pivotal) - A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0116 for correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds.

Principal Investigator with Research Institute of the Southeast Protocol 2029-701-008: Multicenter, Evaluator-blinded, Randomized, Controlled Study of the Safety and Effectiveness of JUVEDERM VOLITE XC Injectable Gel for Improvement in the Neck Appearance.

Principal Investigator with Research Institute of the Southeast (Phase 3) Protocol M21-323: A Phase 3 Multicenter, Open-labeled Extension Study to Evaluate the Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence

Principal Investiagor with Research Institute of the Southeast (Phase 3) Protocol M21-309: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence

Principal Investigator with Research Institute of the Southeast M930521003 (Phase IV) Prospective, multicenter, controlled, evaluator-blind, randomized study to investigate the effectiveness and safety of diluted RADIESSE® for treatment of décolleté wrinkles

Principal Investigator with Research Institute of the Southeast (Phase II) Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC)"

Principal Investigator with Research Institute of the Southeast (Phase II) ET-01-LCL-210: Clinical Trial to Evaluate ET-01 in Subjects with Lateral Canthal Lines

Principal Investigator with Research Institute of the Southeast (Phase II) V01-126A-202: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo ® Forte Gel (0.3% adapalene/2.5% BPO), in the Treatment of Acne Vulgaris

Principal Investigator with Research Institute of the Southeast A Trial to Evaluate the Performance of Placebo Microneedle Arrays in Healthy Human Volunteers (Part I), Followed by Proof of Concept Testing of Efficacy and Safety of Doxorubicin MicroneedleArrays in Subjects with Basal Cell Cancer (Part II)

Principal Investigator with Research Institute of the Southeast Phase 4
43USTT1904 CSP Infraorbital Hollows A randomized, evaluator-blinded, parallel group, no-treatment controlled, multi-center study to evaluate the safety and effectiveness of Restylane-L® for correction of Infraorbital Hollows

Principal Investigator with Research Institute of the Southeast Phase 3 (Pivotal)
BBI-4000-CL-301: A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects with Axillary Hyperhidrosis (the "Cardigan I Study")

Principal Investigator with Research Institute of the Southeast A Multicenter, Open-Label Study to Evaluate the Safety of QM1114-DP for the Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines (READY - 4) 43QM190

Principal Investigator with Research Institute of the Southeast RD.06.SPR.112199 - A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT)

Principal Investigator with Research Institute of the Southeast RD.06.SPR.118169
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

Principal Investigator with Research Institute of the Southeast A Phase 3 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Center Study Investigating the Efficacy and Safety of PF-04965842 and Dupilumab in Comparison with Placebo in Adult Subjects on Background Topical Therapy, with Moderate to Severe Atopic Dermatitis (B7451029)
Principal Investigator- Protocol V01-120A-301 A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
Principal Investigator- M900391004 Evaluation of Effectiveness and Safety of Radiesse (+) for the Improvement of Jawline Volume and Contour
Principal Investigator-Protocol 43USV1704 A Randomized, Evaluator-Blinded, Parallel, Comparator-Controlled Study to Evaluate the Safety and Effectiveness of GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies
Principal Investigator- Protocol ET-01-LCL-207 A Clinical Trial to Evaluate ET-01 in Subjects with Lateral Canthal Lines ET-01-LCL-207
Principal Investigator- Protocol BBI-4000 CL-303 A Multicenter, Randomized, Open-label, Phase 3 Long-term Safety Study of Topically Applied Sofpironium Bromide (BBI-4000) Gel, 5% and 15% in Subjects with Axillary

Hyperhidrosis

Principal Investigator- Protocol LP0162-1337 An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clinical trials

Principal Investigator- EN3835-205 A PHASE 2 OPEN-LABEL STUDY OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY

Principal Investigator 43USK1701 A Randomized, Controlled, Evaluator-Blinded, Multi-Center Study to Evaluate the Effectiveness and Safety of *Restylane® Kysse* versus a Control in the Augmentation of Soft Tissue Fullness of the Lip

Principal Investigator- Protocol V01-123A-301 A Phase 3, Multi-center, Randomized, Double-Blind, Vehicle-Controlled,2 Arm, Parallel-Group Study Comparing the Safety and Efficacy of IDP-123 Lotion and IDP-123 Vehicle Lotion in the Treatment of Acne Vulgaris

Principal Investigator- Protocol V01-126A-201 A Phase 2, Multi-center, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Principal Investigator-MC2-01-C2: A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to MC2-01 Cream Vehicle and Active Comparator in Subjects with Mild-to-Moderate Psoriasis Vulgaris

Principal Investigator-Clinical Trial Protocol LP0084-1369 Incidence of squamous cell carcinoma and other skin neoplasia in subjects with actinic keratosis treated with ingenol disoxate gel 0.018% or 0.037%,or vehicle A phase 3 trial to compare the incidence of SCC and other skin neoplasia on skin areas treated with ingenol disoxate gel or vehicle gel for actinic keratosis on face and chest or scalp A multi-centre, rand omised, open-label, controlled, parallel group, 24-month trial

Principal Investigator- LP0162-1325: Tralokinumab monotherapy for moderate to severe atopic dermatitis. A Randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate –to-severe atopic dermatitis who are candidates for systemic therapy.

Principal Investigator -DRM01B-ACN05: AN OPEN-LABEL STUDY ASSESSING LONG-TERM SAFETY OF OLUMACOSTAT GLASARETIL GEL IN SUBJECTS WITH ACNE VULGARIS

Principal Investigator- DRM01B-ACN03: A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, EFFICACY AND SAFETY STUDY OF OLUMACOSTAT GLASARETIL GEL IN SUBJECTS WITH ACNE VULGARIS

Principal Investigator- EN3835-202: A PHASE 2, OPEN-LABEL EXTENSION STUDY OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY

Principal Investigator- (Pivotal) Voluma-006: A Multi-center, single-blind, randomized,controlled study of the safety and effectiveness of JUVEDERM VOLUMA®XC injectable gel for chin augmentation

Principal Investigator- (Phase 2) EN3835-201: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY

Principal Investigator-(Phase 3) Protocol RD.06.SPR.18251: A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris

Principal Investigator-(Phase 3) LP0084-1193 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Principal Investigator- (Phase 2) A Randomized, Double-blind, Vehicle-Controlled, Parallel-Group Study of the Safety , Tolerability, Bioavailability and Dose-Response of ALX-101 Topical Gel Administered Twice Daily in Adult Subject with Mild to Moderate Atopic Dermatitis

Principal Investigator-(Phase 3) V01-121A-301 - A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Principal Investigator-(Phase 3) DRM04-HH04: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED EFFICACY AND SAFETY STUDY OF DRM04 IN SUBJECTS WITH AXILLARY HYPERHIDROSIS

Investigator- (Phase 2) ANT-1207-HHID-205: Clinical Trial to Evaluate ANT-1207 in the Treatment of Primary Axillary Hyperhidrosis in Adults

Investigator-(Phase 3) LP0105-1032 Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest

Investigator-(Phase 3) An Open-Label Study Assessing Long-Term Safety of DRM04 in Subjects with Primary Axillary

Hyperhidrosis.
Investigator-(Phase 3) A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of DRM04 In Subjects with Axillary Hyperhidrosis.
Investigator-(Phase 2) A multi-center, open label, multiple dose, phase II trial to demonstrate the safety of DWP-450 in adult subjects for treatment of moderate-to-severe glabellar lines.
Investigator-(Phase 3) Protocol Evolus-CLIN-002 Multi-center, randomized, double blind, placebo-controlled, single dose, trial to demonstrate the safety and efficacy of DWP-450 in adult subjects for treatment of moderate-to-severe glabellar lines
Investigator-(Phase 2) A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects with Androgenetic Alopecia (AGA)
Investigator-(Phase 4) Protocol GLI.04.SPR.US10305 Mirvaso In Use Study:Managing Rosacea through assessment and control of its erythema (The Miracle Study)
Investigator-(Phase 2) Protocol LP0084-1014 A multicenter, randomized, double-blind, parallel group, vehicle-controlled, 8 week trial.
Investigator-(Phase 2) Protocol DRM04-HH02 RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, COMPARATOR STUDY OF THE EFFECT OF DRM04B AND DRM04 IN SUBJECTS WITH AXILLARY HYPERHIDROSIS
Investigator-(Phase 2) A Phase 2, Randomized, Double Blind, Vehicle Controlled, Dose-Ranging Study of the Effect of DRM04B in Subjects with Axillary Hyperhidrosis
Investigator-(Phase 2) A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA 15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis.
Investigator-(Phase 2) A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily CLS001 Topical Gels Versus Vehicle Administered for 12 Weeks to Subjects with Acne Vulgaris
Investigator-(Phase 3) A Multicenter, Double-blind, Nontreatment, Long-term Follow-up Study of Subjects who Completed ATX-101 (Deoxycholic Acid Injection) Clinical Trials ATX-101-11-22 or ATX-101-11-23 for the Reduction of Localized Subcutaneous Fat in the Submental Area.
Investigator-(Phase 2) Protocol AUX-CC-831 Randomized, Double-Blind Placebo-Controlled Dose Ranging Study of Repeat Doses of AA4500 For the Treatment of Edematous Fibrosclerotic Panniculopathy.
Investigator-(Phase 3) Protocol 225678-007 A Safety and Efficacy Study to Compare Dapsone dernal Gel with Vehicle Control in Patients with Acne Vulgaris.
Investigator-_(Phase 2) Protocol DRM04-HH01 Randomized, Double-Blind, Vehicle Controlled, Dose-Ranging Study of the effects of DRM04B in Subjects with Axillary Hyperhidrosis.
Investigator- (Phase 2) Protocol LP0105-1012 part 2 Multicentre, randomized, double-blind, parallel group, vehicle-controlled, 8-week trial.
Investigator-_(Pivotal) A prospective, multicenter, within-subject controlled study of the safety and effectiveness of JUVEDERM VOLIFT™ XC versus Restylane-L® for the correction of moderate to severe nasolabial folds.
Investigator- (Phase 2) Protocol ANT-1401-LCL-204: Dose Finding Study of BoNT/A In Subjects With Crow's Feet (Lateral Canthal Lines)
Investigator- (Phase 2) Protocol ANT-1403-HHID-202 Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis in Adults.
Investigator- (Phase 2) Protocol ANT-1401-LCL-203 Clinical Trial to Evaluate ANT-1401 in Subjects with Lateral Canthal Lines.
Investigator- (Phase 3) To evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in increasing overall eyebrow fullness and darkness following bilateral application to the eyebrows of subjects exhibiting eyebrow hypotrichosis.
Investigator A randomized, Evaluator-Blinded, No-Treatment-Controlled Study of the Effectiveness and Safety of Small Particle Hyaluronic Acid plus Lidocaine (SPHAL) in the Augmentation of Soft tissue Fullness of the Lips.
Investigator (Phase 3) Multicenter, randomized, double-blind, placebo-controlled, Phase 3 study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area
Investigator (Phase 4) Multicenter, open label study of ATX-101 (sodium deoxycholate injection) for the reduction of localized subcutaneous fat in submental area.
Investigator-(Phase 1) Clinical Trial To Evaluate ANT 1207 in Subjects with Lateral Canthal Lines.

Investigator-(Phase 1)ANT-1207-101-Acne) Clinical Trial to Evalute Botulinum Neurotoxin Type A (ANT 1207) in Subjects with Acne.
Investigator-(Phase 1)ANT-1207-101-HHID Clinical Trial To Evaluate the Effects of Botulinum Neurotoxin Type A (ANT-1207) For Primary Axillary Hyperhidrosis in Adults.
Investigator- (Phase IV)U0280-403 - Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E foam) versus Vehicle Foam in the Treatment of Chronic Hand Dermatitis.
Investigator-(Phase 1) Clinical Trial To Evaluate The Effects Of Botulinum Neurotoxin Type A (ANT-1207) For Primary Axillary Hyperhidrosis in Adults.
Investigator- A one year, Multicenter, Double-Masked, Randomized, Parallel-Group Study Assessing the Safety and Efficacy of Once Daily Application of Bimatoprost 0.03% Solution Compared to Vehicle to Treat Hypotrichosis of the Eyelashes from Varied Etiologies.
Investigator- A Multicenter, single-blind, randomized, "no-treatment" control study of the safety and effectiveness of JUVEDERM®VOLUMA XC Injectable Gel for cheek augmentation to correct age-related volume deficit in the mid face.
Investigator-(Phase III)111482 A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma.
Investigator- 1402604 An exploratory, multi-center, investigator-blinded, active-controlled study to investigate the efficacy of topical azelaic acid (AzA) 15% gel twice daily or metronidazole topical gel 1% once daily, plus anti-inflammatory dose doxycycline (40mg) once daily in subjects with moderate papulopustular rosacea.
Investigator- (Phase IIIb) Protocol Number: GW01-0901 A Phase IIIb, Randomized, Double-Blinded, Placebo-Controlled,Multi-Center, Efficacy and Safety Study of 3.75% Imiquimod Cream Following Cryosurgery for the Treatment of Actinic Keratoses
Investigator- A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and impetigo Due to Methicillin-Resistant Staphylococcus aureus.
Investigator-(Pilot Study) A Clinical Evaluation Comparing the Needle Disengagement Rates for Syringes of JUVEDERM ULTRA Injectable Gel with a 5mm Luer-Lock Pitch and Tyco Needle vs. a 3mm Luer-Lock Pitch and a TSK-A6 Needle.
Investigator- (Phase IV) Open-Label, Randomized, Split-Face Study to Evaluate the Efficacy, Safety and Subject Satisfaction of Pain Management During and After Restylane® Dermal Filler Injections for the Correction of Nasolabial Folds.
Investigator- Efficacy and Safety of a Topical Five Product System Used in Combination with Dermatological Laser/Light Treatment Based Facial Cosmetic Procedures-Pilot Study.
Investigator- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Two Doses of S-777469 (400 mg BID) in Patients with Atopic Dermatitis.
Investigator-, A Follow-up Study to Evaluate, Sustained Clearance Rates of Actinic Keratosis up to One Year after Completion of Studies GW01-0702, GW01 0704, and GW01-0705.
Investigator-(Phase 3), Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Six Weeks of Treatment with Imiquimod Creams for Actinic Keratoses.
Investigator- A Randomized, Evaluator-Blinded, Parallel Group Light Dose Ranging Study of Photodynamic Therapy with Levulan Topical Solution + Blue Light in Moderate to Severe Facial Acne Vulgaris.
Investigator- Observer-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Effects if a Single Bilateral Topical Treatment of Botulinum Type A (BTXA) to Peri-Orbital Wrinkles.
Investigator-(Pilot study) A Multi-Center, Open Label Study Of The Safety And Effectiveness Of JUVEDERM Ultra Injection Gel In Subjects Who Desires Lip Enhancement.
Investigator- (Phase III-IV), Multi-Center, Open-Label Extension Study to Assess the Long-Term Safety of Repeat Administrations of Reloxin in the Treatment of Glabellar Lines.
Investigator-(Pilot Study)A Clinical Evaluation Comparing the Needle Disengagement Rates for Syringes of JUVEDERM ULTRA Injectable Gel with a 3 mm Luer-Lock Pitch vs. a 5 mm Luer-Lock Pitch.
Investigator-(Pilot Study) A Multi-center, double-blind, randomized, parallel-controlled, prospective comparison of the Tyco Monoject 30G ½ needle versus the HART 30G ½ needle when used in clinical practice with JUVEDERM ULTRA Injectable Gel for the treatment of moderate to severe nasolabial folds.
Investigator-(Phase III) An Open-Label, Multi-Center, Uncontrolled, Single-Group Assignment, Long Term Safety Study of 4% Trade Name (Fluorouracil) Cream in Subjects with Actinic Keratosis (who participated in the Phase III studies).
Investigator-(Pilot Study) A Multi-center, open-label, non-comparison trial design JET (Juvederm Experience Trial)
Investigator-(Phase III), Randomized, Placebo-Controlled, Multi-Center, Double-Blind Study of the Safety and Duration of

Efficacy of Reloxin (Botulinum Type A Toxin) in Correction of Moderate to Severe Glabellar Lines (and including a Sub-Study to Detect Any Treatment-Related QT Interval Changes)
Investigator- (Phase III), Multi-Center, Randomized, Double-blind, Vehicle-Controlled, 4-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of Clindaben (1/2.5) Gel, Clindaben Vehicle, Clindamycin (1%), and Benzoyl Peroxide (2.5%) Gels in the Treatment of Moderate to Severe Acne Vulgaris
Investigator – (Pilot Study) Juvederm Experience Trial for correction of moderate to severe nasolabial folds and have had their nasolabial folds treated with Restylane within the last 12 months.
Investigator – A Randomized, Double Blind, Vehicle-Controlled Multi-Center Study of the Safety and efficacy of 4% Fluorouracil Cream Versus its Vehicle Cream in the Treatment of Actinic Keratosis
Investigator- Comparative Evaluation of the Fabric Bleaching potential of Duac Topical Gel and Benzaclin when used for the Treatment of Facial Acne Vulgaris – Pilot Study
Investigator-1520-IMIQ-03 Open-label Safety and Pharmacokinetic Study of Aldara for Actinic Keratosis.
Investigator-A Randomized, Double blind, Placebo Controlled, Parallel Study Evaluating the Efficacy of S-Caine Peel (Lidocaine 7% and Tetracaine 7% Cream) to Provide Local Dermal Anesthesia for Pulsed Dye Laser Therapy in Adults.
Investigator-An Open-Label Safety Study to Evaluate the use of S-Caine Peel (Lidocaine 7% and Tetracaine 7% Cream) in Adult Patients Undergoing a Minor or Major Dermal Procedure.

Investigator- Protocol A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the effects of COL-101 (Doxycycline Monohydrate Capsules) MR, 40 MG administered once daily in conjunction with Azelaic Acid Gel, 15% (Finacea) for the treatment of Rosacea.
Investigator- (Phase III) A Randomized Double-blind, Double-Dummy, Multicenter, Non inferiority Phase III Study to Assess the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily, versus Oral Cephalexin, 500mg in Adults, or 12.5mg/kg (250mg/5ml) in Children, Twice Daily, in the treatment of Secondarily Infected Dermatoses.
Investigator- (Phase IIIb), Open-Label Effectiveness and Safety Study of Imiquimod 5% Topical Cream in The Treatment of Actinic Keratosis.
Investigator- A Multicenter, Open-label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects with Psoriasis. (Ease Study)
Investigator – A Double Blind, Placebo-Controlled Study to Evaluate the Improvement of Joint and Skin Disease Subjects with Psoriatic Arthritis Receiving Enbrel (Amgen)
Investigator –(Phase IV)A Single Center, Double Blinded, Placebo Controlled Study Of Botox for the Treatment of Subjects with Chin Rhytides Involving the Mentalis Muscle (Allergan)
Sub-Investigator –(Phase IV) A Randomized, Double Blind, Placebo Controlled Parallel Study to Assess the Safety and Efficacy of Rosiglitazone in the Treatment of In Chronic Plaque Psoriasis (Glaxo)
Principal Investigator- A placebo controlled study of low dose doxycycline for the treatment or rosacea Collagenex)

Community Service:
Duke Children's Hospital – Camp Kaleidoscope Board Member
Massachusetts General Hospital Cancer Center Fund Raising
Suncoast Community High School Foundation Board of Directors
Arthur R Marshall Foundation for the Everglades- Board of Directors

Media:
Contributor to : The New York Times, Wall Street Journal, USA Today, Time, Elle, Allure, Good Housekeeping, Vogue, Cosmopolitan, Self, Marie Claire, Shape, Fitness and New Beauty
Contributor to NewsMax Health
Featured on the Martha Stewart Show
Featured on local NBC/ABC/CBS news affiliates
Featured on CBS Early Show Live

Curriculum Vitae Kenneth Beer, M.D.

Textbook Editor:
Beer, K; Botulinum Toxins for Cosmetic Treatment; Informa Publishing;
London, England; 2014

Beer, K; Tosti, A; Complications in Cosmetic Surgery, Springer, London, England, 2012

Beer, K et al; Textbook of Cosmetic Dermatology & Surgery: The Cosmetic Bootcamp Textbook; Informa Publishing; London, England; 2010

Beer, K; Tosti, A; "Acne Scars: Classification and Treatment." Informa Publishing; London, England – December 2009

Chapters in Textbooks:
Beer, K; Treatment of Acne Scars with Fractional Lasers in and Tosti, A; "Acne Scars: Classification and Treatment." Informa Publishing; London, England – December 2009

Beer, K; "Cytokines and Peptides" in Draelos, Z; Berson, D; Lupo, M, "Textbook of Cosmeceuticals" - 2009

Beer, K; "Botulinum Toxins" in Jones J, "Textbook of Cosmetic Dermatology"; Wiley Publishing; Hoboken, NJ: USA – 2009

Beer, K; Poly Lactic Acid for Draelos et al Comprehensive Text of Cosmetic Dermatology; Blackwell Publishing; Edinburgh, UK – 2009

Beer, K; Chapter 1 The approach to the Cosmetic Patient; In: Hirsch, R; Sadick, N; Cohen, J et al Aesthetic Rejuvenation a Regional Approach; McGraw-Hill Companies 2009.

Beer, K; Seminars in Cutaneous Medicine and Surgery: Update in Aesthetic Dermatology; Guest Editor 25:3 September 2006

Beer K., Lowe N. NewFill: A New Material in Subdermal Sculpting; Procedures in Cosmetic Dermatology Series, Volume 4, Chapter 10; Elsevier 2005

PUBLICATIONS:
Beer, K; Avellar, R.; The Relationship Between Delayed Reactions to Dermal Fillers and Biofilm: Fact and Fiction. Journal of Dermatologic Surgery. In Press.

Beer, K; Bayers, S; Beer, J; Aesthetic Treatment Considerations for the Eyebrows and Periorbital Complex. Jan 2014, Volume 13, Issue 1

Bayers, S; Kapp, D; Beer, K; Slavin, B. Treatment of Positive Basal Carcinoma With Vismodegib: Case Report and Consideration of Treatment Options and Their Implications. Journal of Drugs in Dermatology. Jan 2014, Volume 13, Issue 1

Beer KR, Julius H, Dunn M, Wilson F. Treatment of Eyebrow Hypotrichosis Using Bimatoprost: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study. Dermatol Surg. April 2013

Beer, K; Importing Injectables; The Dermatologist; March 2013

Beer, K; Merkel Cell Carcinoma: Bridging the Gap; The Journal of Dermatologic Surgery, Inc. 2013; 39:239.

Minokadeh, A.; Wulkan, A.; Beer, K.; Waibel, J.; Merkel Cell Carcinoma; Dermatology for the Clinician Volume 11 Issue 1:1-2; January/February 2013

Beer, K; A Challenging Eruption; The Journal of Drugs in Dermatology. December 2012, Volume 11, Issue 12:1494-5 Review.

Waibel, J.; Wulkan, A.; Lupo, M.; Beer, K.; Anderson, R.; Treatment of Burn Scars With the 1,550 nm Nonablative Fractional Erbium Laser; Lasers in Surgery and Medicine 44:441–446; 2012

Beer, K.; Jeanine Downie; Jacob Beer; A Treatment Protocol for Vascular Occlusion from Particulate Soft Tissue Augmentation; The Journal of Clinical and Aesthetic Dermatology Volume 5, Number 5; May 2012

Beer, K.; Wilson, F.; Skin Cooling Provides Minimal Relief of Patient Discomfort During Periocular Botulinum Toxin Type A Injection; Dermatologic Surgery. June 2011 Volume 37, Issue 6: 870-2

Beer, K; Combined Treatment for Skin Rejuvenation and Soft-Tissue Augmentation of the Aging Face; Journal of Drugs in Dermatology. Feb 2011, Volume 10, Issue 2:125-32 Review.

Beer, K; Combined Treatment for Skin Rejuvenation and Soft-Tissue Augmentation of the Aging Face; Journal of Drugs in Dermatology. Feb 2011, Volume 10, Issue 2:125-32 Review.

Beer, K; Boyd, C; Patel, R; Bowen, B; James S; Brian, M; Rapid Onset of Response and Patient-Reported Outcomes after Onabotulinumtoxina Treatment of Moderate-to-Severe Glabellar Lines. The Journal of Drugs in Dermatology. Jan 2011, Volume 10, Issue 1:39-44

Narurkar, V; Beer, K; Cohen, J; An Open-Label Trial Examining the Efficacy and Safety of a Pre and Postprocedure Topical Five-Product System (Clinique Medical Optimizing Regimen) Specifically Formulated to Complement Laser/Light-Based Facial Cosmetic Procedures. Dec, 2010. J Cosmetic Laser Therapy, Volume 12, Issue 6:288-95; e-Poster to be presented at the 29th ASLMS Annual Conference, April 2009.

Beer, K; Oakley, H.; Axillary Chromidrosis: Report of a Case, Review of the Literature and Treatment Considerations. Journal Cosmetic Dermatology Dec 2010; Volume 9, Issue 4:318-20

Beer, K; Oakley, H; Clinical and Histopathologic Correlation of an Eruption Secondary to Taxotere; Journal of Drugs in Dermatology Dec 2010, Volume 9, Issue 12:1534-5

Beer, K; Lupo, M; Making the Right Choices: Attaining Predictable Aesthetic Results With Dermal Fillers; Journal of Drugs in Dermatology May 2010, Volume 9, Issue 5:458-65

Hanke, C.W; Beer, K; Stockfleth, E; Wu, J; Rosen, T; Levy, S; Imiquimod 2.5% and 3.75% for the treatment of actinic keratosis: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles; Journal of American Academy of Dermatology; Volume 62; Number 4; April 2010

Beer, K; Chapter 2 Proteins and Cytokines Used for Rejuvenation; In Sadick, N; Lupo, M; Berson, D; Draelos, Z; et al Cosmeceutical Science in Clinical Practice (Series in Cosmetic and Laser Therapy); Informa Healthcare April 2010

Boyd, C; Beer, K; James, S; Beddingfield, F; Assessing Earlier Onset of Action of Onabotulinumtoxin A in the Treatment of Glabellar Lines by Age and Race; Poster presented at the American Academy of Dermatology, March 2010.

Tosti, A; Beer, K; De Padova, Maria; Management of Complications of Cosmetic Procedures Handling Common and More Uncommon Problems; Springer-Verlag; 2010

Beer, K; Cost Effectiveness of Botulinum Toxins for the Treatment of Depression: Preliminary Observations; Journal of Drugs in Dermatology; Volume 9, Issue 1; January 2010

Beer, K; Chapter 1 Treatment of Platysmal Bands with Botulinum Toxin; In Alam, M; Pongprutthipan, M; et al Body Rejuvenation; Springer Science + Business Media, LLC 2010

Beer, K; Solish, N; Hyaluronics for Soft-Tissue Augmentation: Practical Considerations and Technical Recommendations; Journal of Drugs in Dermatology; Volume 8, Issue 12; December 2009

Beer, K; Dermal Fillers and Combination of Fillers for Facial Rejuvenation; Dermatology Clinic; Dermatol Clin 27; Elsevier Inc. 2009

Beer, K; Kellner, E; Beer, J; Cosmeceuticals for Rejuvenation; Guest Editor; Facial Plastic Surgery Journal, Volume 25, Number 5; January 2010

Beer, K; Beer, J; Overview of Facial Aging; Guest Editor; Facial Plastic Surgery Journal, Volume 25, Number 5; January 2010

Beer, K; Oakley, H; Waibel, J; Perioral Abscess Associated with Isotretinoin; Journal of Drugs in Dermatology; Volume 8, Issue 11; November 2009

Beer, K; Cohen, J; Goldman, M; Lupo, M; Supplement to the Dermatology Directory 2009 Second Edition; Physicians' Continuing Education Corporation; 2009

Beer, K; Delayed Onset Nodules from Liquid Injectable Silicone: Report of a case, Evaluation of Associated Histopathology and Results of Treatment with Minocycline and Celocoxib; Journal of Drugs in Dermatology; Volume 8; Issue 10; October 2009

Fagien, S; Maas, C; Thomas, J.; Murphy, D.; Beddingfield III, F. Treating Investigator Kenneth R. Beer, MD. Juvederm ULTRA for Lip Enhancement: An Open-Label, Multi-Center Study. Poster is presented at the American Society for Aesthetic Plastic Surgery, May 2009.

Waibel, J; Beer, K; Narurkar, V; Alster, T; Preliminary Observations on Fractional Ablative Resurfacing Devices: Clinical Impression; Journal of Drugs in Dermatology; Volume 8; Issue 5; May 2009

Beer, K; The Beer Hand Scale: A Validated Scale to Grade Dorsal Hand Aging and Response to Treatments; Journal of Drugs in Dermatology; Volume 8; Issue 4 (Supplement); April 2009

Beer, K; Waibel, J; Disfiguring Scarring Following Mesotherapy-Associated *Mycobacterium cosmeticum* Infection. Journal of Drugs in Dermatology; Vol. 8 Issue 4. April 2009.

Treatment of This Region With Soft- Tissue Augmentation Products; Journal of Drugs in Dermatology; Volume 8; Issue 4 (Supplement); April 2009

Solish, Nowell; Beer, K; Remington, K; A Grading System for the Malar Crease Region and its Implications for Treatment of This Region With Soft- Tissue Augmentation Products; Journal of Drugs in Dermatology; Volume 8; Issue 4 (Supplement); April 2009

Monheit, G; Beer, K; Thomas, J; Murphy, D; Canfield, W. Digital three-dimensional imaging for quantifiable measurement of lip augmentation with a 24 mg/mL hyaluronic acid gel implant. JAAD Supplement P3509; Vol. 60 No. 3; March 2009.

Waibel, J; Beer, K; Ablative Fractional Laser Resurfacing for the Treatment of a Third-degree Burn. Journal of Drugs in Dermatology; Vol 8; Issue 3. March 2009.

Beer, K; Clinicopathologic Correlation of Delayed-Onset Periorbital Poly-L-Lactic Acid Nodules; The Journal Dermatologic Surgery – 2009

Beer, K: Waibel, J: Recurrent Basal Cell Carcinoma Discovered Using Positron Emission Tomography (PET) Scanning: Journal of Drugs in Dermatology; Volume 7: Issue 9; September 2008

Beer, K; Narins, R; Soft Tissue Augmentation; Chapter 19; In: Kaminer, Michael et al Atlas of Cosmetic Surgery May 2008

Beer, K; Delayed Complications from Threadlifting: Report of a Case, Discussion of Treatment Options and Consideration of Implications for Future Technology; The Journal of Dermatologic Surgery; - May 2008

Beer K, Yohn M, Cohen JL. Evaluation of injectable CaHA for the treatment of mid-face volume loss. The Journal of Drugs in Dermatology. 2008 Apr;7(4):359-66.

Beer, K; Waibel, J; Fractional Laser Resurfacing for Thermal Burns; The Journal of Drugs in Dermatology; Volume 7; Issue 1; January 2008

Beer, K A Single-Center, Open-Label Study of the Use of Injectable Poly-L-Lactic Acid for the Treatment of Moderate to Severe Scarring from Acne or Varicella; The Journal of Drugs in Dermatology; Volume 33; Number 22; Special Issue December 2007

Beer, K; Waibel, J. Botulinum Toxin Type A Enhances the Outcome of Fractional Resurfacing of the Cheek; The Journal of Drugs in Dermatology; Volume 6; Issue 11; November 2007

Beer, K. A Randomized, Evaluator-Blinded, Comparison of Efficacy of Hyaluronic Acid Gel and Avian-Sourced Hylan B Plus Gel for Correction of Nasolabial Folds; Journal of Dermatologic Surgery 2007; 33:1-9; August 2007
Beer, K; Cohen, Joel; Narins, Rhoda; Injectable Fillers; Roenigk's Dermatologic Surgery; Chapter 70; Third Edition 2007

Beer, K. Fractional Resurfacing Update; Cosmetic Dermatology; Vol.20 No.8 August 2007

Beer, K. Radiesse Nodule of the Lips from a Distant Injection Site: Report of a Case and Consideration of Etiology and Management; Journal of Drugs in Dermatology; Volume 6; Issue 8; August 2007

Beer, K, Narins, R; Photorejuvenation; In Shiffman, Melvin et al Simplified Facial Rejuvenation; Chapter 20; 2007

Beer, K; Narins, R; Narins, D; Thermage Radiofrequency; In Shiffman, Melvin et al Simplified Facial Rejuvenation; Chapter 18; 2007

Beer K, Downie J Sequelae from Inadvertent Long-Term use of Potent Topical Steroids. The Journal of Drugs in Dermatology. 2007 May;6(5):550-1.

Beer, K; Solish, N. Reshaping the Nose with Injectable Agents; Cosmetic Dermatology; December 2006 Volume 19 No. 12

Beer, K; Cohen, J; Upper Face Rejuvenation; Cosmetic Dermatology; September 2006 Vol. 19 No. 9

Beer, K; Lupo, M; Cohen, J; Rendon, M; Novel Eye Cream Containing Mixture of Human Growth Factors and Cytokines for Treatment of Aged Skin Around Eyes; Presented at the American Academy of Dermatology 65th Annual Meeting.

Beer, K; Comparison of the Fabric Bleaching Potential and Tolerability of Two 5% Benzoyl Peroxide/1% Clindamycin Gels Used to Treat Facial Acne Vulgaris; Presented at the 2006 American Academy of Dermatology Meeting

Narins, RS; Beer, K; Liquid Injectable Silicone: A Review of Its History, Immunology, Technical Considerations, Complications and Potential; Plastic & Reconstructive Surgery; September 1 Supplement, 2006

Beer, K; Nasal Reconstruction Using 20 mg/ml Cross-Linked Hyaluronic Acid; The Journal of Drugs in Dermatology. May 2006 Volume 5 Issue 5 465-466

Curriculum Vitae Kenneth Beer, M.D.

Beer, K; Dialogues in Dermatology; New Aspects of Cosmetic Dermatology; May 2006 Volume 58, no. 2

Beer, K; Utilization of Poly-L-lactic Acid for Aesthetic Rejuvenation; Supplement to Cosmetic Dermatology; April 2006 Vol 19 No.4 S2

Beer K; Comparative Evaluation of the Safety and Efficacy of Botulinum Toxin Type A and Topical Creams for Treating Moderate to Severe Glabellar Rhytids; The Journal of Drugs in Dermatology; 2006:32; 184-192

Narins, RS, Cohen, J, Beer, K; Injectable Skin Fillers Chapter in The Journal of Drugs in Dermatology, Roenigk and Roenigk

Beer K. A Double-Blinded, Placebo-Controlled Study of Botox for the Treatment of Subjects with Chin Rhytids. Journal of Drugs in Dermatology, July/August 2005.

Beer K, Matarrasso S, Injectable Collagens. Procedures in Cosmetic Dermatology Series, Volume 4, Chapter 3; Elsevier 2005

A Double Blinded, Placebo Controlled Study of Botox Cosmetic for the Treatment of the Mentalis Muscle. Presented at American Society for Dermatologic Surgery 2003 meeting.

Beer, K., Botulinum Toxin Type Microinjections: The Use of a 32-Gauge Needle to Diminish Pain. Cosmetic Dermatology. July 2003; 12-14.

Beer, K., Hand Rejuvenation with Autologous Fat Transfer, Cosmetic Dermatology, 16, 2003, 15-16

Beer, K et al. Fluoxetine-Induced Hypersensitivity. Int. Journal of Dermatology. 1994; 130:803-804.

Beer, K et al. Corp Rends in Oral Pemphigus. Int. Jour. of Dermatology. 1994; 33:190-191.

Beer, K et al. Insecticide Induced Lupus. Int.Jour. of Dermatology. 1994; 33:860-862

Beer, K et al. Intravascular Fasciitis Int. Journal. of Dermatology. 1996; 35:414-415

Fretzin D, Sloan J, Fretzin S and Beer, K. Eccrine Syringofibroadenoma, A Clear Cell Variant. Am Jour Dermatopath.1995; 17(6): 591-593.

Beer, K; Medenica M. Solitary Porokeratotic Eccrine Ostial and Dermal Duct Tumor in a sixty-year old man. Int. Journ.of Dermatology. 1996; 35:310-311

Hospital Privileges:
Good Samaritan Center 09/1995-present
Jupiter Medical Center 03/2009-present
University of Miami
St. Mary's Medical Center 11/1995-present